Standout Papers

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal... 2004 2026 2011 2018 2.8k
  1. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer (2009)
    Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine
  2. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease (2010)
    Jean‐Frédéric Colombel, William J. Sandborn et al. New England Journal of Medicine
  3. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD (2004)
    Marco Daperno, Geert D’Haens et al. Gastrointestinal Endoscopy
  4. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017)
    William J. Sandborn, Chinyu Su et al. New England Journal of Medicine
  5. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis (2011)
    William J. Sandborn, Gert Van Assche et al. Gastroenterology
  6. A Simple Classification of Crohnʼs Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 (2000)
    Christoph Gasché, Jürgen Schölmerich et al. Inflammatory Bowel Diseases
  7. A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis (2006)
    Geert D’Haens, William J. Sandborn et al. Gastroenterology
  8. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease (1999)
    Paul Rutgeerts, Geert D’Haens et al. Gastroenterology
  9. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab (2007)
    William J. Sandborn, Paul Rutgeerts et al. Annals of Internal Medicine
  10. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis (2015)
    Noortje Rossen, Susana Fuentes et al. Gastroenterology
  11. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum (1998)
    Geert D’Haens, Karel Geboes et al. Gastroenterology
  12. Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease (2009)
    Filip Baert, Liesbeth Moortgat et al. Gastroenterology
  13. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease (2012)
    Geert D’Haens, Marc Ferrante et al. Inflammatory Bowel Diseases
  14. Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial (1999)
    Geert D’Haens, Sander van Deventer et al. Gastroenterology
  15. The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016)
    Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut
  16. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed (2014)
    Bruce E. Sands, Brian G. Feagan et al. Gastroenterology
  17. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial (2012)
    Paul Rutgeerts, Gert Van Assche et al. Gastroenterology
  18. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis (2016)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  19. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis (2021)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  20. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis (2015)
    Johannan F. Brandse, Gijs R. van den Brink et al. Gastroenterology
  21. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017)
    Julián Panés, William J. Sandborn et al. Gut
  22. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis (2019)
    William J. Sandborn, Filip Baert et al. Gastroenterology
  23. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis (2020)
    William J. Sandborn, Subrata Ghosh et al. Gastroenterology
  24. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease (2023)
    Edward V. Loftus, Julián Panés et al. New England Journal of Medicine
  25. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023)
    William J. Sandborn, Séverine Vermeire et al. The Lancet
  26. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2023)
    Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine
  27. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study (2022)
    William J. Sandborn, Geert D’Haens et al. Gastroenterology

Immediate Impact

2 by Nobel laureates 4 from Science/Nature 207 standout
Sub-graph 1 of 12

Citing Papers

IL-10 constrains sphingolipid metabolism to limit inflammation
2024 StandoutNature
Crohn's disease
2024 Standout
194 intermediate papers

Works of Geert D’Haens being referenced

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 Standout
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
2022 Standout
and 143 more

Author Peers

Author Last Decade Papers Cites
Geert D’Haens 30399 23520 11890 897 41.6k
Laurent Peyrin‐Biroulet 32828 24374 12865 1.1k 47.8k
Bruce E. Sands 27560 20316 10502 579 38.2k
Silvio Danese 28863 20178 12757 1.3k 48.6k
Remo Panaccione 25603 18908 9789 684 35.4k
Gert Van Assche 26295 20158 10425 445 35.8k
Edward V. Loftus 25630 21033 13328 755 36.2k
Brian G. Feagan 40888 31094 14136 747 52.5k
Jean‐Frédéric Colombel 41043 31226 15887 711 57.3k
Paul Rutgeerts 47645 36937 16107 554 63.7k
Subrata Ghosh 16550 11912 8246 583 29.9k

All Works

Loading papers...

Rankless by CCL
2026